These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 4148857)

  • 1. Emotional functions in short-term vs. long-term L-Dopa therapy in Parkinsonism.
    Maskin MB; Riklan M; Chabot D
    J Clin Psychol; 1973 Oct; 29(4):493-5. PubMed ID: 4148857
    [No Abstract]   [Full Text] [Related]  

  • 2. A preliminary study of selected emotional changes in Parkinsonians on L-dopa therapy.
    Maskin MB; Riklan M; Chabot D
    J Clin Psychol; 1972 Oct; 28(4):604-5. PubMed ID: 5080854
    [No Abstract]   [Full Text] [Related]  

  • 3. Psychological studies of longer range L-DOPA therapy in Parkinsonism.
    Riklan M; Halgin R; Maskin M; Weissman D
    J Nerv Ment Dis; 1973 Dec; 157(6):452-64. PubMed ID: 4148472
    [No Abstract]   [Full Text] [Related]  

  • 4. Does levodopa alter depression and psychopathology in Parkinsonism patients?
    Marsh GG; Markham CH
    J Neurol Neurosurg Psychiatry; 1973 Dec; 36(6):925-35. PubMed ID: 4149286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term treatment of Parkinsonism with L-dopa.
    Presthus J; Holmsen R
    Acta Neurol Scand Suppl; 1972; 51():131-2. PubMed ID: 4514340
    [No Abstract]   [Full Text] [Related]  

  • 6. [Long-term treatment of Parkinsonism with L-dopa].
    Presthus J; Holmsen R
    Tidsskr Nor Laegeforen; 1972 Nov; 92(33):2262-6. PubMed ID: 4630916
    [No Abstract]   [Full Text] [Related]  

  • 7. Effects of "short-term" versus "long-term" L-Dopa therapy in parkinsonism on critical flicker frequency.
    Maskin MB; Riklan M; Chabot D
    Percept Mot Skills; 1974 Apr; 38(2):455-8. PubMed ID: 4363091
    [No Abstract]   [Full Text] [Related]  

  • 8. [Effect of dioxyphenylalanine (L-DOPA) on extrapyramidal motoric hyperkineses after prolonged neuroleptic therapy].
    Hippius H; Logemann G
    Arzneimittelforschung; 1970 Jul; 20(7):894-6. PubMed ID: 5536051
    [No Abstract]   [Full Text] [Related]  

  • 9. L-dopa for parkinsonism.
    Reveno WS; Bauer RB; Rosenbaum H
    Geriatrics; 1973 Jan; 28(1):86-8. PubMed ID: 4683093
    [No Abstract]   [Full Text] [Related]  

  • 10. [Advances in L-DOPA therapy for parkinsonism through combination with a decarboxylase inhibitor. Results of a long-term study].
    Wälzholz U; Schönfelder H
    Nervenarzt; 1972 Oct; 43(10):531-2. PubMed ID: 4628192
    [No Abstract]   [Full Text] [Related]  

  • 11. [Long term treatment of a parkinsonism with l-dopa].
    Presthus J
    Tidsskr Nor Laegeforen; 1973 Oct; 93(28):2111-3. PubMed ID: 4590069
    [No Abstract]   [Full Text] [Related]  

  • 12. Long-term treatment of parkinsonism with levodopa.
    Boshes B
    Postgrad Med; 1971 Dec; 50(6):94-9. PubMed ID: 5001838
    [No Abstract]   [Full Text] [Related]  

  • 13. Behavioral effects of l-dopa in man.
    Goodwin FK
    Semin Psychiatry; 1971 Nov; 3(4):477-92. PubMed ID: 5173049
    [No Abstract]   [Full Text] [Related]  

  • 14. [L-DOPA therapy of parkinsonism].
    Refsum S
    Nord Med; 1969 May; 81(18):570-1. PubMed ID: 5768311
    [No Abstract]   [Full Text] [Related]  

  • 15. [L-DOPA-and dopa-decarboxylase inhibitor combination for the treatment of Parkinsonism].
    Fujimori N; Kito S; Yamamoto M; Itoga E; Kosaka K
    Nihon Rinsho; 1974 Mar; 32(3):579-86. PubMed ID: 4859014
    [No Abstract]   [Full Text] [Related]  

  • 16. [Clinical effect of L-DOPA and electromyographic study of Parkinsonism].
    Sato G; Ito H; Handa Y; Takahashi I; Iijima K
    No To Shinkei; 1971 Mar; 23(3):325-32. PubMed ID: 5107821
    [No Abstract]   [Full Text] [Related]  

  • 17. [Quantitative testing methods for objectification of the effect of prolonged L-dopa therapy in parkinsonism].
    Gerstenbrand F; Grünberger J; Schubert H
    Nervenarzt; 1973 Aug; 44(8):428-33. PubMed ID: 4733895
    [No Abstract]   [Full Text] [Related]  

  • 18. Clinical analyses of factors influencing L-dopa treatment of Parkinson's syndrome.
    Granerus AK; Steg G; Svanborg A
    Acta Med Scand; 1972; 192(1-2):1-11. PubMed ID: 4559530
    [No Abstract]   [Full Text] [Related]  

  • 19. Cognitive and perceptual effects of long-range L-dopa therapy in Parkinsonism.
    Hamel AR; Riklan M
    J Clin Psychol; 1975 Apr; 31(2):321-3. PubMed ID: 1133201
    [No Abstract]   [Full Text] [Related]  

  • 20. L-Dopa (L-3,4-dihydroxyphenylanine)--its clinical effects in parkinsonism.
    Yahr MD; Duvoisin RC; Hoehn MM; Schear MJ; Barrett RE
    Trans Am Neurol Assoc; 1968; 93():56-63. PubMed ID: 4885744
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.